Nextgen to launch an inbound medical tourism program

list

Nextgen, a biotech company within the Artgen Biotech Group (MOEX: ABIO), is preparing to launch an inbound medical tourism program in Russia for patients from the People’s Republic of China.

Nextgen will be offering Chinese citizens treatment for chronic lower limb ischemia (CLLI) with its proprietary drug, Neovaskulgen. Once the clinical trials for the drug for other indications have been completed, domestic and foreign patients will also have the opportunity to be treated in Russia for diabetic foot and interstitial cystitis.

The program's focus on guests from the People's Republic of China is a deliberate strategy. China is the most significant target market for attracting international tourists.

In early June 2024, Nextgen conducted a series of workshops at four hospitals in China as part of this program:

  • The First Affiliated Hospital of Harbin Medical University
  • The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine (including Hanan Branch)
  • The First Hospital of Harbin
  • The First Hospital of Heilongjiang Province

The objective of these workshops was to provide training to doctors who will be involved in the selection of Chinese patients planning to receive medical care with Neovaskulgen in Russia.

Neovasculgen is actively used in practical healthcare for the treatment of lower limb ischemia. It is the world’s first gene therapy drug registered in the Russian Federation, with ‘therapeutic angiogenesis’ (therapeutic vascular growth) as the mode of action. Neovasculgen is included in the VED list, as well as in national recommendations, federal clinical and statistical groups, and the Moscow MHI program.

Neovasculgen has the potential to treat other diseases where an increase in vasculature density is required, in particular, diabetic foot, interstitial cystitis, and alopecia, due to its ability to stimulate therapeutic angiogenesis and target the treatment of tissue ischemia. At present, Nextgen is concentrating its efforts on expanding the drug’s indications.

Nextgen JSC is a resident of MedTech and a resident of the Lomonosov cluster of the Vorobyovy Gory Innovation Science and Technology Center of the Moscow State University. The company is engaged in the development and implementation of gene therapy drugs, with the goal of expanding the indications for the use of Neovasculgen.